<International Circulation>: There didn’t seem to be much drop in blood pressure.
Prof. Kjeldsen: Blood pressure was the same. Blood pressure came down. Both office blood pressure and ambulatory blood pressure were the same with ACE and ACE CCB combination. Despite that there was a difference in the primary cardiovascular endpoint which was 20%. Still， in my opinion， the most important thing is to get the blood pressure down but there may be certain benefits from certain drug combinations， RAS inhibitor， CCB on top of standard treatment for blood pressure.
<International Circulation>: Do you have any idea why it brought down the cardiovascular endpoint if it did not bring down blood pressure?
Prof. Kjeldsen: There are benefits beyond the lowering of blood pressure. The atherosclerotic process as we saw in another presentation by Carlos Ferrario shows how these drugs work on the atherosclerotic process. They work on thrombosis， plaque formation， lipids and other additional effects beyond blood pressure. This can be explained from animal and experimental research.
[下一页] [1] 2 [3] [上一页]